Endometriosis: Seven-Market Drug Forecast and Market Analysis to 2034

1.1 The endometriosis market will exhibit considerable growth from 2024 to 2034
1.2 Key players will continue their competitive position in the endometriosis market over the forecast period
1.3 Current therapies leave significant unmet needs in the endometriosis market
1.4 Late-stage pipeline drugs entering the endometriosis market are poised to drive growth
1.5 What do physicians think?

2.1 Catalyst
2.2 Related reports
2.3 Upcoming reports

3.1 Etiology and pathophysiology
3.2 Classification or staging systems

4.1 Disease background
4.2 Risk factors and comorbidities
4.3 Global and historical trends
4.4 Forecast methodology
4.5 Epidemiological forecast for endometriosis (2024-34)
4.6 Discussion

5.1 Diagnosis and treatment overview
5.2 KOL insights on disease management

6.1 Overview

7.1 Overview
7.2 Non-invasive diagnostics
7.3 Disease awareness and education of medical professionals
7.4 More effective drugs with long-term safety and tolerability
7.5 Non-hormonal therapies
7.6 Better understanding of the disease etiology and pathophysiology

8.1 Overview
8.2 Clinical trials design

9.1 Overview
9.2 Promising drugs in clinical development

10.1 Overview
10.2 Competitive assessment

11.1 Overview
11.2 Deal-making trends

12.1 Global markets
12.2 US
12.3 5EU
12.4 Japan

13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
13.4 Primary research - KOLs interviewed for this report
13.5 Primary research - prescriber survey
13.6 About the Authors

• About the Analyst
• Contact the Publisher

Table 1: Endometriosis: key metrics in the 7MM
Table 2: Role of the different theories in the pathogenesis of endometriosis
Table 3: Classifications of endometriosis
Table 4: Risk factors and comorbidities for endometriosis
Table 5: The most used guidelines by country
Table 6: Top 10 deals by value, 2020-25
Table 7: Endometriosis market - global (7MM) drivers and barriers, 2024-34
Table 8: Key events impacting sales for endometriosis in the US, 2024-34
Table 9: Endometriosis market - drivers and barriers in the US, 2024-34
Table 10: Key events impacting sales for endometriosis in the 5EU, 2024-34
Table 11: Endometriosis market - drivers and barriers in the 5EU, 2024-34
Table 12: Key events impacting sales for endometriosis in Japan, 2024-34
Table 13: Endometriosis market - drivers and barriers in Japan, 2024-34
Table 14: High-prescribing physicians (non-KOLs) surveyed, by country

Figure 1: Global sales forecast by country for endometriosis in 2024 and 2034
Figure 2: Analysis of the company portfolio gap in endometriosis during the forecast period
Figure 3: Competitive assessment of the late-stage pipeline agents that the analyst expects to be licensed for the treatment of endometriosis during the forecast period
Figure 4: Roles of estrogen receptor a and estrogen receptor ß in normal endometrium and endometrial lesions
Figure 5: Endometrial lesions of varying depth
Figure 6: Sources of estradiol in endometriosis tissue and targets of the current medical therapy
Figure 7: 7MM, diagnosed incidence of endometriosis (cases per 100,000 population), women, ages 12-54 years, 2024
Figure 8: 7MM, diagnosed prevalence of endometriosis (%), women, ages 12-54 years, 2024
Figure 9: 7MM, sources used and not used to forecast the diagnosed incident cases of endometriosis
Figure 10: MM, sources used and not used to forecast the diagnosed prevalent cases of endometriosis
Figure 11: 7MM, sources used to forecast the laparoscopy confirmation status for the diagnosed prevalent cases of endometriosis
Figure 12: 7MM, sources used to forecast the diagnosed prevalent cases of endometriosis by ASRM stage
Figure 13: 7MM, sources used to forecast the diagnosed prevalent cases of endometriosis by phenotype
Figure 14: 7MM, sources used to forecast the diagnosed prevalent cases of endometriosis by comorbidities
Figure 15: 7MM, diagnosed incident cases of endometriosis, N, women, ages 12-54 years, 2024
Figure 16: 7MM, diagnosed incident cases of endometriosis by age, N, women, 2024
Figure 17: 7MM, laparoscopy confirmation status for the diagnosed incident cases of endometriosis, N, women, ages 12-54 years, 2024
Figure 18: 7MM, diagnosed prevalent cases of endometriosis, N, women, ages 12-54 years, 2024
Figure 19: 7MM, diagnosed prevalent cases of endometriosis by age, N, women, 2024
Figure 20: 7MM, laparoscopy confirmation status for the diagnosed prevalent cases of endometriosis, N, women, ages 12-54 years, 2024
Figure 21: 7MM, diagnosed prevalent cases of endometriosis by ASRM stage, N, women, ages 12-54 years, 2024
Figure 22: 7MM, diagnosed prevalent cases of endometriosis by phenotype, N, women, ages 12-54 years, 2024
Figure 23: 7MM, diagnosed prevalent cases of endometriosis by comorbidities, N, women ages 12-54 years, 2024
Figure 23: Sample endometriosis treatment algorithm
Figure 25: Unmet needs and opportunities in endometriosis
Figure 26: Overview of the development pipeline in endometriosis
Figure 27: Key late-stage trials for the promising pipeline agents that the analyst expects to be licensed for endometriosis in the 7MM during the forecast period
Figure 28: Competitive assessment of the promising pipeline agents that the analyst expects to be licensed for endometriosis in the 7MM during the forecast period
Figure 29: Competitive assessment of the marketed and pipeline drugs benchmarked against the GnRH antagonist, Orilissa
Figure 30: Competitive assessment of the marketed and pipeline drugs benchmarked against the hormonal contraceptives
Figure 31: Competitive assessment of the marketed and pipeline drugs benchmarked against the subcutaneous agent, Zoladex
Figure 32: Analysis of the company portfolio gap in endometriosis during the forecast period
Figure 33: Global (7MM) sales forecast by country for endometriosis in 2024 and 2034
Figure 34: Sales forecast by class for endometriosis in the US in 2024 and 2034
Figure 35: Sales forecast by class for endometriosis in the 5EU in 2024 and 2034
Figure 36: Sales forecast by class for endometriosis in Japan in 2024 and 2034